Categories
Tags
Authors: Toljan K, Vrooman B PMID: 30248938 PMCID: PMC6313374 DOI: 10.3390/medsci6040082 Abstract Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 [...]
Categories: I-RECOVER Long Covid, I-RECOVER Post-Vaccine
Tags: naltrexone
Auhtors: Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG PMID: 27279602 DOI: 10.3892/ijo.2016.3567 Abstract It has been reported that lower doses of the opioid antagonist naltrexone are able to reduce tumour growth by interfering with cell signalling as well as by modifying the immune system. We have evaluated the gene expression [...]
Categories:
Tags: naltrexone
Authors: Younger J, Parkitny L, McLain D PMID: 24526250 PMCID: PMC3962576 DOI: 10.1007/s10067-014-2517-2 Abstract Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous [...]
Categories: I-RECOVER Long Covid, I-RECOVER Post-Vaccine
Tags: naltrexone